Briefs from primary sources
The stream: Regulation
Two-sentence briefs on FDA announcements, Federal Register documents and ClinicalTrials.gov records, each linked to its source.
Machine-summarized from primary sources; not independently reported. How we use automation
Friday, October 16, 2026
-
FDA announces support for forward compatibility of eCTD 4.0
The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research announced support for forward compatibility of Electronic Common Technical Document (eCTD) Version 4.0. This notice informs stakeholders that submissions based on eCTD 4.0 are supported for forward compatibility.
Source: Federal Register notice, October 16, 2026
Thursday, October 15, 2026
-
FDA authorizes emergency use of four animal drugs for New World screwworm
The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use.
Source: Federal Register notice, October 15, 2026
Wednesday, October 14, 2026
-
FDA launches Rare Disease Framework Initiative to gather public feedback
The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry.
Source: FDA press announcement, October 14, 2026
Monday, October 12, 2026
-
Medtronic announces preliminary results of MiniMed exchange offer
Medtronic says its exchange offer to swap MiniMed shares for Medtronic ordinary shares was oversubscribed, with 298,024,452 Medtronic shares tendered. Medtronic intends to accept 55,032,401 shares for 252,813,348 MiniMed shares, estimating about 18.3% of tendered shares will be exchanged.
Source: Company press release (PR Newswire), October 12, 2026
Saturday, October 10, 2026
-
FDA finalizes guidance on post-approval manufacturing changes to biosimilars
FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance.
Source: Federal Register notice, October 13, 2026
-
FDA final rule permits salt substitutes in standardized foods
The rule, effective December 14, 2026, amends FDA's standards of identity to permit the use of salt substitutes in standardized foods. The change is intended to reduce sodium content in these foods.
Source: Federal Register rule, October 13, 2026
Friday, October 9, 2026
-
FDA corrects withdrawal notice of 16 ANDAs
The FDA issued a correction to a June 3, 2026 notice that announced the withdrawal of approval of 16 abbreviated new drug applications, effective July 6, 2026. The correction removes entries for ANDA 207366, ANDA 212957, and ANDA 218638, noting that Navinta LLC requested the approvals not be withdrawn, so those approvals remain in effect.
Source: Federal Register notice, October 9, 2026
-
FDA withdraws approval of Amneal's celecoxib ANDA
FDA withdraws approval of abbreviated new drug application 208833 for celecoxib capsules 50 mg, 100 mg, 200 mg, and 400 mg held by Amneal Pharmaceuticals of New York, LLC. Amneal requested the withdrawal and waived its opportunity for a hearing.
Source: Federal Register notice, October 9, 2026
-
FDA withdraws approval of 37 ANDAs
The agency is withdrawing approval of 37 abbreviated new drug applications from multiple applicants. The applicants notified the FDA that the drug products were no longer marketed and requested the approvals be withdrawn.
Source: Federal Register notice, October 9, 2026
-
FDA issues priority review voucher for ZANVASTRO
FDA approved ZANVASTRO on September 3, 2026. FDA issued a priority review voucher to the sponsor, Ionis Pharmaceuticals, Inc., after determining the product meets the criteria under the FD&C Act.
Source: Federal Register notice, October 9, 2026
-
FDA classifies hematopoietic cell enrichment kit as class II device
The order designates the kit as a class II device with special controls. The special controls will be part of the codified language for classification of the hematopoietic cell enrichment kit.
Source: Federal Register rule, October 9, 2026